Has Meghan Dupont received payments from drug or device companies?

Yes. Drug and device makers reported $5,780 in general payments to Meghan Dupont across 296 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Meghan Dupont did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Meghan Dupont come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Meghan Dupont

Psychiatric/Mental Health · New Orleans, LANPI 1730856618

Payments from drug & device makers

$5,780in general payments, 2019–2025

Across 296 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$908
Johnson & Johnson$770
Alkermes, Inc.$735
AbbVie$718
Teva Pharmaceuticals USA, Inc.$623
Indivior Inc.$623
plus $1K from 10 others

What the payments were for

Food & beverage$5,771100%
Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	43	$908
Johnson & Johnson	29	$770
Alkermes, Inc.	35	$735
AbbVie	40	$718
Teva Pharmaceuticals USA, Inc.	43	$623
Indivior Inc.	31	$623
Otsuka America Pharmaceutical, Inc.	23	$560
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	15	$264
Lundbeck LLC	18	$219
Axsome Therapeutics, Inc.	6	$108
E.r. Squibb & Sons, L.L.C.	4	$73
Gilead	3	$65
Vanda Pharmaceuticals Inc.	2	$45
Sunovion Pharmaceuticals Inc.	2	$38
Braeburn Inc.	1	$16
Polynovo North America LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,780 in reported general payments places this provider in the 85th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega SustennaPaliperidone Palmitate	43	$135,901
Austedo XrDeutetrabenazine	11	$89,734
VraylarCariprazine Hcl	15	$22,225
Fluphenazine Decanoate	25	$3,816
Quetiapine Fumarate	187	$3,546
Ziprasidone Hcl	55	$3,054
Divalproex Sodium ErDivalproex Sodium	64	$2,507
Mirtazapine	88	$2,184
Risperidone	159	$2,042
Haloperidol Decanoate	38	$1,671
Benztropine Mesylate	86	$1,342
Vilazodone Hcl	11	$1,269
Duloxetine Hcl	50	$1,266
Venlafaxine Hcl ErVenlafaxine Hcl	44	$1,246
Memantine Hcl	14	$1,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonInvega Sustenna	$770	$135,90143 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr	$623	$89,73411 claims
AbbVieVraylar	$718	$22,22515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in New Orleans

Kelly RobinsonNew Orleans$23K
Amy LacoutureBaton Rouge$663K
Amanda EymardHouma$617K
Amber LittlefieldBroussard$225K
Timothy PellegrinHouma$210K
Melissa GuilbeauLafayette$122K
Kimberly ForcinelShreveport$92K
Sattaria DilksLake Charles$57K
Joe TaylorHammond$38K
Lecy AlbaradoScott$34K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →